.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Accenture
QuintilesIMS
Medtronic
Johnson and Johnson
Harvard Business School
Merck
Queensland Health
US Army
US Department of Justice

Generated: December 12, 2017

DrugPatentWatch Database Preview

US Patents With Foreign Priority to United Kingdom Patent: 0602747.8

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
NovartisAFINITOReverolimusTABLET;ORAL022334-001Mar 30, 2009RXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC
NovartisAFINITOReverolimusTABLET;ORAL022334-002Mar 30, 2009RXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC
NovartisAFINITOReverolimusTABLET;ORAL022334-003Jul 9, 2010RXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC
NovartisAFINITOReverolimusTABLET;ORAL022334-004Mar 30, 2012RXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Table 'thinkbio_newdpw.patent_gazette' doesn't exist